AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34419109
Drug: Simethicone solution
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone solution intake > 60 minutes before procedure (group 3)
Trial: 35594075
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) with four monthly injections
Trial: 35594075
Drug: Modified combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified combination group with two bimonthly IVB injections and modified laser therapy
Trial: 34708929
Drug: Task-shared, nurse-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-shared, nurse-delivered cognitive-behavioral therapy for adherence and depression (CBT-AD)
Trial: 32196976
Drug: Tafamidis 61-mg
RxNorm normalized name: tafamidis 61 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 61-mg free acid capsules
Trial: 32196976
Drug: Tafamidis meglumine
RxNorm normalized name: Tafamidis meglumine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis meglumine 80-mg (4 × 20-mg) capsules
Trial: 32473644
Drug: Cardiac Shockwave
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Shockwave Therapy (SWT) during CABG surgery
Trial: 34143970
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus pegylated liposomal doxorubicin (PLD) (40 mg/m2 intravenously every 4 weeks)
Trial: 32051303
Drug: Melatonin (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (four doses of 10 mg each)
Trial: 32051303
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosing regime as melatonin)
Trial: 34981479
Drug: Curcumin capsules
RxNorm normalized name: curcumin Oral Capsule
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin capsules with piperine supplement (500 mg/day, 95% curcuminoids) for 8 weeks
Trial: 35704960
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement containing standardized menthol, limonene, and gingerol, administered for 30 days in addition to standard treatment.
Trial: 35704960
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered for 30 days in addition to standard treatment.
Trial: 34256715
Drug: Internet delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet delivered Cognitive Behavior Therapy with exposure (ICBT)
Trial: 34256715
Drug: Internet delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet delivered Cognitive Behavior Therapy without exposure (ICBT-WE)
Trial: 33257279
Drug: Dipyrone 25
RxNorm normalized name: dipyrone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 25 mg kg−1 every 24 hours
Trial: 33257279
Drug: Dipyrone 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 12.5 mg kg−1 every 12 hours
Trial: 33257279
Drug: Meloxicam 0.1
RxNorm normalized name: MELOXICAM 0.15 g in 100 mL ORAL SUSPENSION [Metacam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 0.1 mg kg−1 every 24 hours
Trial: 33257279
Drug: Rescue analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue analgesia (tramadol, 2 mg kg−1 IV)
Trial: 33239135
Drug: Ginsenoside treatment
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside treatment
Trial: 33991178
Drug: Sodium-glucose co-transporter-2
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-glucose co-transporter-2 inhibitors (SGLT2i)
Trial: 35377518
Drug: Onabotulinum toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onabotulinum toxin injections (12 units, 1:2.5)
Trial: 35377518
Drug: Onabotulinum toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onabotulinum toxin injections (6 units, 1:5)
Trial: 35377518
Drug: Onabotulinum toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onabotulinum toxin injections (4 units, 1:7.5)
Trial: 35377518
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline injection
Trial: 34215615
Drug: Control (non-HC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-HC treatment)
Trial: 33202219
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose, 90 mg twice daily for 30 days)
Trial: 33202219
Drug: Clopidogrel (300–600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300–600 mg loading dose, 75 mg daily for 30 days)
Trial: 36189651
Drug: Polynucleotides and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polynucleotides and hyaluronic acid based gel
Trial: 32565458
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen + oral hydromorphone
Trial: 32565458
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen + oral acetaminophen
Trial: 35328964
Drug: Inertial training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inertial training (twice per week for 6 weeks, training load of about 70% of maximal force)
Trial: 33974370
Drug: Isotonic ophthalmic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic ophthalmic solution of 0.5% ozonised oil in liposomes plus hypromellose treatment (2 drops 4 times/day)
Trial: 32419540
Drug: Fractional CO2-assisted
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2-assisted photodynamic therapy (FrCO2 + PDT)
Trial: 32925788
Drug: Acupoint thread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint thread embedding treatment
Trial: 32925788
Drug: Climen tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climen tablet (0.3 mg, 1 tablet/day)
Trial: 36070301
Drug: oral alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral alfacalcidol
Trial: 34076288
Drug: Spironolactone therapy
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone therapy (Group PVI/SP)
Trial: 36327532
Drug: Internet-based emotional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based emotional awareness and expression therapy (I‐EAET) for 10 weeks
Trial: 34530594
Drug: Rivaroxaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (5 mg twice a day) alone
Trial: 34530594
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg once a day) alone
Trial: 36404687
Drug: Combined agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined agent flurbiprofen 8.75 mg and cetylpyridinium chloride 1.0 mg in the form of tablets for resorption
Trial: 33491594
Drug: β-alanine supplementation
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-alanine supplementation (6.4 g·d-1) for 28 days
Trial: 34281854
Drug: RANKL inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RANKL inhibitors (RANKL-I)
Trial: 33506810
Drug: Early low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early low-molecular-weight heparin (LMWH) administration within 7 days from COVID-19 signs and symptoms onset
Trial: 33506810
Drug: Delayed low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed low-molecular-weight heparin (LMWH) administration after 7 days
Trial: 33506810
Drug: Early low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early low-molecular-weight heparin (LMWH) administration
Trial: 33811776
Drug: Adsorbent lotion
RxNorm normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbent lotion containing tapioca starch, spent grain wax, Butyrospermum parkii extract, argania spinosa kernel oil, aloe barbadensis, rosehip oil, and allantoin applied twice daily.
Trial: 33811776
Drug: Adsorbent lotion
RxNorm normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbent lotion
Trial: 33811776
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone cream applied twice daily.
Trial: 33811776
Drug: Adsorbent lotion
RxNorm normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbent lotion and 1% hydrocortisone cream
Trial: 34238698
Drug: Ultrasound-guided BOTOX
RxNorm normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided BOTOX injection
Trial: 34238698
Drug: Electrocauterization after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrocauterization after removal of apocrine sweat glands followed by ultrasound-guided BOTOX injection after two weeks
Trial: 32481441
Drug: Sufentanil 1.78
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1.78 µg/kg (group S)
Trial: 32481441
Drug: Nalbuphine 1.78
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 1.78 mg/kg (group N)
Trial: 32045638
Drug: HES50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES50 (50 mg kg‐1 hesperidin)
Trial: 32045638
Drug: HES75 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES75 (75 mg kg‐1 hesperidin)
Trial: 32045638
Drug: HES100 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES100 (100 mg kg‐1 hesperidin)
Trial: 32045638
Drug: HES150 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES150 (150 mg kg‐1 hesperidin)
Trial: 32045638
Drug: HES50-150 (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES50-150 (50-150 mg kg‐1 hesperidin)
Trial: 34433653
Drug: Spartalizumab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab (400 mg once every 4 weeks)
Trial: 34433653
Drug: Chemotherapy (per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (per investigator's choice)
Trial: 35077474
Drug: rasagiline (monotherapy)
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rasagiline (monotherapy)
Trial: 34337284
Drug: ATTUNE knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATTUNE knee implant system
Trial: 34337284
Drug: P.F.C. SIGMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.F.C. SIGMA knee implant system
Trial: 34987324
Drug: Dry needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling with conventional therapy
Trial: 34987324
Drug: Neural mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural mobilization with conventional therapy
Trial: 32966163
Drug: Self-reported success
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported success in treatment, beliefs about the importance of multidimensional treatment, and self-reported empathy.
Trial: 35932067
Drug: Transport PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transport PLUS intervention (administered by trained EMTs)
Trial: 35931131
Drug: Vaginal hysterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal hysterectomy with uterosacral ligament suspension (USLS)
Trial: 32777032
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of clinicians' antibiotic prescribing rate (80.2%)
Trial: 32777032
Drug: Lowest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest quartile of clinicians' antibiotic prescribing rate (42.1%)
Trial: 35263558
Drug: Antihistamine-releasing contact
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen)
Trial: 35263558
Drug: Placebo contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contact lens (etafilcon A with no added drug)
Trial: 32730798
Drug: Osilodrostat (1–30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osilodrostat (1–30 mg twice daily)
Trial: 35789381
Drug: SER-109 (investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER-109 (investigational oral microbiome therapeutic)
Trial: 34749808
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Calcium polyP microparticles (Ca‐polyP MPs) and biphasic calcium phosphate (BCP)
Trial: 36275772
Drug: 50 µg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg bivalent NoV vaccine
Trial: 36275772
Drug: 150 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 µg bivalent NoV vaccine
Trial: 36275772
Drug: Both dose
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dose levels of the vaccine
Trial: 35875694
Drug: 1200 IU
RxNorm normalized name: Vitamin E 1200 IU Oral Capsule, Liquid Filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 IU (30 µg) capsules of vitamin D3 once per day
Trial: 35875694
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil capsules once per day
Trial: 32130806
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy with dolutegravir-abacavir-lamivudine
Trial: 33081083
Drug: Rose extract
RxNorm normalized name: evening primrose extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rose extract treatment
Trial: 33616606
Drug: Cancer drugs
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer drugs with positive reimbursement recommendation
Trial: 33616606
Drug: Cancer drugs
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer drugs with negative reimbursement recommendation
Trial: 34311777
Drug: Candidate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate treatment (specific candidates not mentioned)
Trial: 32722956
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day thiamin supplements
Trial: 32968994
Drug: Second ARTA
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second ARTA therapy
Trial: 34369452
Drug: Incremental vestibulo-ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental vestibulo-ocular reflex (VOR) adaptation (IVA) training, once daily for 15 minutes over 6 months
Trial: 34369452
Drug: x1 training,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: x1 training, once daily for 15 minutes over 6 months
Trial: 32584828
Drug: Tracking of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tracking of daily prosocial behavior
Trial: 35437302
Drug: Genetic screening
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic screening and insulin resistance markers
Trial: 32938386
Drug: Dezocine 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 0.03 mg/kg (diluted to 5 mL)
Trial: 34601233
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (1-hour education session and daily mindfulness exercises during hospitalization)
Trial: 34793637
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of ropivacaine 0.5% (experimental group)
Trial: 34793637
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of ropivacaine 0.5% (control group)
Trial: 38939518
Drug: anti-PD1 treatment
RxNorm normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD1 treatment
Trial: 34171233
Drug: PCV10 vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV10 vaccination schedule (two-dose) at ages 2 and 6 months (group D)
Trial: 32370765
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) + standard of care (SOC) treatments
Trial: 32370765
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) palliative-intent treatments
Trial: 34875624
Drug: Evening whey
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening whey protein supplement
Trial: 34098771
Drug: Control (simple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (simple hydration treatment)
Trial: 34098771
Drug: Alprostadil treatment
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil treatment
Trial: 35988576
Drug: Upadacitinib 45
RxNorm normalized name: upadacitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 45 mg once-daily
Trial: 35988576
Drug: Upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 15 mg once-daily
Trial: 35988576
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg once-daily
Trial: 34293127
Drug: Low-sodium DASH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium DASH diet (1150 mg sodium)
Trial: 34293127
Drug: High-sodium control
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium control diet (3450 mg sodium)
Trial: 32161366
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (IN‐OT) administration (24 IU/day for 4 weeks)
Trial: 33596412
Drug: WiSE system
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WiSE system (leadless endocardial system) for cardiac resynchronization therapy
Trial: 32580161
Drug: Nordic hamstring
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordic hamstring exercise training performed twice a week (n = 17)
Trial: 32969758
Drug: Reldesemtiv (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reldesemtiv (all doses combined)
Trial: 32474564
Drug: 24h-SIRI/B (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24h-SIRI/B (oral S-1 with 24-h infusion of irinotecan plus bevacizumab)
Trial: 34613338
Drug: Genetically lower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically lower level of non-HDL cholesterol (17 mg/dL)
Trial: 34946289
Drug: Intervention-1 (IG-1):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention-1 (IG-1): Complementary training with traditional means of physical therapy
Trial: 33407747
Drug: 25% albumin
RxNorm normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% albumin infusion
Trial: 33407747
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride infusion
Trial: 35870895
Drug: Weekly physical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly physical activity (PA) scheduled
Trial: 35870895
Drug: Weekly energisers
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly energisers (short classroom PA breaks) scheduled
Trial: 32826188
Drug: MMA injections
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMA injections combined with corticosteroids (ropivacaine, morphine, methylprednisolone)
Trial: 36123067
Drug: CytoSorb haemoadsorption
RxNorm normalized name: DRESSING,CUTISORB ULTRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CytoSorb haemoadsorption along with standard surgical treatment
Trial: 36123067
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment alone
Trial: 36167573
Drug: Oral co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-trimoxazole 960 mg once daily for 18 months
Trial: 35861446
Drug: Subcutaneous hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous hydration (hypodermoclysis)
Trial: 36305633
Drug: CJM112 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJM112 75 mg